REGN Regeneron Pharmaceuticals, Inc.

930.21USD+0.74%Mkt Cap: 95.52B USDP/E: 20.41

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammator…

Insiders, last 90 daysNet sellers
Institutional holders20 on file

Key Statistics

Company
Market Cap95.52B USD
Enterprise Value86.06B USD
Revenue (TTM)16.90B USD
Gross Profit12.24B USD
Net Income (TTM)4.50B USD
Revenue/Share164.24 USD
Last Price930.21 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees15.4K
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)20.41
P/E (Forward)12.99
PEG1.15
EV/EBITDA15.24
EV/Revenue5.09
P/S5.65
P/B2.77
EPS (TTM)45.24 USD
EPS (Forward)71.10 USD
52W Range
591.5285% of range991.73
52W High991.73 USD
52W Low591.52 USD
Profitability
Gross Margin85.35%
Oper. Margin30.38%
EBITDA Margin33.42%
Profit Margin31.41%
ROE14.41%
ROA11.11%
ROIC12.57%
ROCE10.23%
Growth
Revenue Growth36.30%
Earnings Growth35.50%
Cash Flow & Leverage
Operating CF4.98B USD
CapEx (TTM)1.21B USD
FCF Margin15.27%
FCF Yield2.70%
Net Debt-6.59B USD
Net Debt/EBITDA-1.17
Net Debt/FCF-2.56
Balance Sheet
Debt/Equity0.09
Current Ratio3.35
Quick Ratio2.72
Book Value/Sh333.93 USD
Cash/Share92.69 USD
Dividends
Fwd Div Rate3.76 USD
Trail. Div Rate3.70 USD
Div. Yield0.40%
5Y Avg Yield—
Payout Ratio8.18%
Ex-Div DateNov 20, 2026
Pay DateDec 3, 2026
Analyst Consensus
Rating1.8 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)990.81 USD
Upside (mean)+6.5%
Target Range812.00 USD – 1175.00 USD
812.00+6.5% to mean1175.00
# Analysts27
Ownership
Shares Out.101.63M
Float96.36M
Insiders2.15%
Institutions92.37%
Short Interest
Short Ratio2.9d
Short % Float2.27%
Short % Out.2.14%
Shares Short2.22M
Short (prev mo.)2.15M
Technical
SMA 50824.37 (+12.8%)
SMA 200749.90 (+24.0%)
Beta0.10
S&P 52W Chg12.00%
Avg Vol (30d)891.29K
Avg Vol (10d)985.21K
Technical Indicators
RSI (14)58.0
MACD37.0998
MACD Signal39.2573
MACD Hist.-2.1575
BB Upper1026.02 USD
BB Middle907.12 USD
BB Lower788.22 USD
BB Width26.22%
ATR (14)30.09 USD
Vol Ratio (20d)0.71x

About Regeneron Pharmaceuticals (NASDAQ: REGN)

›

Regeneron Pharmaceuticals (NASDAQ: REGN) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 15,410 employees.

The shares were at 930.21 USD on 20 November 2026, up 43.3% over 52 weeks. Its 52-week range is 591.52 USD to 991.73 USD: the price is 6.2% below the high and 57.3% above the low.

At a market capitalisation of 95.52B USD, it trades at 20.4 times trailing earnings and 13.0 times forward earnings. The median trailing P/E of its 13 largest Biotechnology peers is 34.3, a discount of 41% for REGN. It pays a dividend yielding 0.40% (it pays out 8% of its earnings), against a median of 1.39% among the dividend payers in that peer group.

Regeneron Pharmaceuticals reports return on equity of 14.4%, an operating margin of 30.4% and revenue up 36.3% year over year.

It holds more cash than debt, a net cash position of 6.59B USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 27 analysts cover the stock, with an average rating of Buy; their mean price target of 990.81 USD is 6.5% above the current price. The next earnings report is expected on 28 January 2027.